Browsing Tag
Andreessen Horowitz
38 posts
Armadin secures $255.5m Series B as AI security valuation tops $2.5bn
Armadin has secured $255.5 million in Series B financing at a valuation above $2.5 billion, putting fresh capital behind an ambitious attempt to automate offensive cybersecurity as artificial intelligence changes the speed and scale of digital attacks.
EliseAI valuation jumps to $4bn after $350m raise as vertical AI growth accelerates
EliseAI raised $350 million at a $4 billion valuation as its housing and healthcare AI business expands. Find out what is driving its rapid growth.
Adaptive lands $30m Series B as AI agents move deeper into project accounting
Adaptive has secured $30 million in Series B funding led by Tidemark, taking total capital to $57 million as more than 750 construction companies use its project-accounting platform and the startup expands AI agents across job costing, WIP, billing, payments and compliance.
U.S. Navy places up to $200m Blackbeard production order with Castelion
The U.S. Navy has placed a production delivery order worth up to $200 million for Castelion’s Blackbeard hypersonic weapon, advancing the programme beyond early operational prototypes as the startup deploys fresh private capital into manufacturing scale.
Heron Power secures $60m credit facility as Factory One moves toward production
Heron Power has added a $60 million credit facility after its $140 million Series B as it converts a 286,000-square-foot California warehouse into a high-volume factory for 5 MW medium-voltage power systems.
Thyme Care crosses $2bn valuation as $7bn oncology platform expands into new businesses
Thyme Care has secured more than $125 million from Morgan Health, Humana, CVS Health Ventures and other investors at a valuation above $2 billion. The company is already profitable, reaches 10.5 million people and manages more than $7 billion of oncology spending. Its next move is more ambitious: turning the cancer-care platform into a parent company that can attack drug costs, biosimilar adoption and clinical-trial access.
Sirius brings real-time AI decisioning to subscription cancellations after a16z Speedrun
Sirius has emerged from Andreessen Horowitz’s a16z Speedrun with an AI platform that decides how to respond when subscribers try to leave, while early traction points to a potentially larger autonomous retention category.
River AI’s $1.1bn war chest: Can a four-month-old neolab crack enterprise AI?
Igor Babuschkin's River AI has landed $1.1 billion with Nvidia and AMD Ventures backing, squeezing closed-source labs on enterprise fine-tuning economics.
Volta Infra hits $2.4bn valuation as AI cloud buildout tests Europe’s compute ambitions
Volta Infra has reportedly raised funding at a $2.4 billion valuation and secured a $10 billion AI infrastructure agreement, but investors must decide whether Europe’s AI cloud capacity can scale fast enough to justify the hype.
Braveheart Bio IPO targets $1.2bn valuation as HCM drug race heats up
Braveheart Bio is seeking up to $318.8 million in its Nasdaq IPO, but investors must decide whether its cardiac myosin inhibitor can compete in an increasingly crowded hypertrophic cardiomyopathy market.